|
    KVUE U.S.: NYSE

    Kenvue Inc.

    KVUEUS
    Premarket
    Last Updated: Sep 8, 2023 4:09 a.m. EDT Delayed quote

    $ 20.99

    -0.02 0.00%
    Before Hours Volume: 5
    Close Chg Chg %
    $20.99 -1.39 -6.21%
    Advanced Charting
    Volume: 102.65M 65 Day Avg: 32.38M
    317% vs Avg
    20.96 Day Range 22.58
    20.96 52 Week Range 27.80

    Partner Center

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    KVUE Overview

    Key Data

    • Open $22.44
    • Day Range 20.96 - 22.58
    • 52 Week Range 20.96 - 27.80
    • Market Cap $42.86B
    • Shares Outstanding 1.91B
    • Public Float 1.73B
    • Beta 0.27
    • Rev. per Employee $672.48K
    • P/E Ratio 23.05
    • EPS $0.91
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 93.93M 08/15/23
    • % of Float Shorted 5.43%
    • Average Volume 32.38M

    Performance

    5 Day
    • -8.58%
    1 Month
    • -11.51%
    3 Month
    • -16.37%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 14 Full Ratings

    Recent News

    Read full story

    Kenvue Stock Falls 6%. It May Be Fears on Tylenol Lawsuits.

    Read full story

    J&J Dividend Decision Shows Power of Free Cash Flow

    Health Care Flat on Rotation out of Defensive Sectors -- Health Care Roundup

    Read full story

    Johnson & Johnson Revises Guidance After Kenvue Spinout. There’s Good News on the Dividend.

    J&J revises 2023 sales, profit outlook lower after Kenvue separation, will maintain dividend

    Read full story

    Kenvue Fits Right In With Other Dividend Aristocrats

    Read full story

    J&J’s Kenvue Exchange Offer Was a Big Win for the Little Guy

    Read full story

    The Nvidia Distraction Is Over. Jackson Hole, Powell, Bonds Take Center Stage.

    Read full story

    J&J Makes It Official: Kenvue Stock Swap Was a Huge Hit With Shareholders

    J&J Accepts 191M Shares in Exchange for 1.53B Kenvue Shares, Finalizing Separation

    Kenvue becomes ‘fully independent’ after final separation from J&J

    Read full story

    J&J’s Exchange Offer for Kenvue Is Tricky From a Tax Standpoint. What to Do.

    Read full story

    Kenvue Will Join the S&P 500 Friday. It Could Boost the Stock.

    Emergent Biosolutions Shares Fall 5%; Company to Exit SmallCap 600

    J&J spinoff Kenvue to replace Advance Auto Parts on the S&P 500

    Healthcare Shares Move Higher -- Healthcare Roundup

    Read full story

    J&J’s Kenvue Exchange Offer Was Too Popular. What Happens to Shares Now.

    J&J says Kenvue tender offer was oversubscribed, expects 23.8% of tendered shares will be exchanged

    Read full story

    Fed’s Powell Will Walk an Economic Tightrope. Why Markets May Not Like It.

    Read full story

    Tylenol Litigation Could Be a Headache for Kenvue

    Kenvue Unusual Options Activity

    on Benzinga.com

    Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023

    on Benzinga.com

    1 Brand-New Dividend Stock Income Investors Won't Want to Miss

    on Motley Fool

    Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023

    on Benzinga.com

    Is J&J a Buy After the Kenvue Separation?

    on Motley Fool

    Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories

    on Benzinga.com

    Johnson & Johnson's Growth Strategy Post Tylenol Parent Kenvue Split: Paving the Way for Medical Innovation

    on Benzinga.com

    Is This Incredible Dividend Stock Still a Buy Following Its Recent Split?

    on Motley Fool

    Kenvue Unusual Options Activity For September 01

    on Benzinga.com

    J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation

    on Zacks.com

    Johnson & Johnson Reveals Updated 2023 Projections After Finalizing Biggest Shake Up In 135 Years

    on Benzinga.com

    1 Top Dividend Stock to Buy Hand Over Fist Right Now

    on Motley Fool

    7 Very Oversold Warren Buffett Stocks to Buy Right Now

    on InvestorPlace.com

    3 Stocks to Buy That Can Beat a Bear Market

    on Motley Fool

    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet

    on Benzinga.com

    New Buy Rating for Kenvue, Inc. (KVUE), the Technology Giant

    on TipRanks.com

    Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023

    on Benzinga.com

    Kenvue, Inc. (KVUE) was upgraded to a Buy Rating at Goldman Sachs

    on TipRanks.com

    Kenvue Unusual Options Activity

    on Benzinga.com

    J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange

    on Zacks.com

    Kenvue Inc.

    Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women’s health and wound care. The firm’s history roots back to the year 1880, when Johnson & Johnson was founded. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.